Chemistry: molecular biology and microbiology – Measuring or testing process involving enzymes or... – Involving antigen-antibody binding – specific binding protein...
Reissue Patent
2007-09-04
2007-09-04
Nguyen, Bao-Thuy L. (Department: 1641)
Chemistry: molecular biology and microbiology
Measuring or testing process involving enzymes or...
Involving antigen-antibody binding, specific binding protein...
C435S007930, C435S007940, C435S969000, C435S970000, C435S973000, C435S975000, C436S807000, C436S808000, C436S810000, C436S514000, C436S518000, C436S528000, C436S530000, C422S067000, C422S067000
Reissue Patent
active
11117772
ABSTRACT:
A diagnostic tool is disclosed for accurately and rapidly diagnosing the condition of an ailing organ. Although applicable to numerous organ and organ systems, this application particularly illustrates the concept of conjunctive marker utilization as it relates to diagnosing and distinguishing congestive heart failure. The invention particularly relates to the conjunctive utilization of cardiac Troponin I (cTn-I) and natriuretic peptide, e.g. ANP, pro-ANP, BNP, pro-BNP and CNP as a retrospective tool for diagnosing the underlying mechanism of heart failure and as a prospective analytical device for monitoring disease progression and efficacy of therapeutic agents.
REFERENCES:
patent: 5290678 (1994-03-01), Jackowski
patent: 5580722 (1996-12-01), Foulkes et al.
patent: 5604105 (1997-02-01), Jackowski
patent: 5747274 (1998-05-01), Jackowski
patent: 5786163 (1998-07-01), Hall
patent: 5795725 (1998-08-01), Buechler et al.
patent: 6117644 (2000-09-01), Debold
patent: 6156521 (2000-12-01), Buechler et al.
patent: 6162902 (2000-12-01), Mischak et al.
patent: 6174686 (2001-01-01), Buechler et al.
patent: 2003/0022235 (2003-01-01), Dahlen et al.
patent: 2003/0109420 (2003-06-01), Valkirs et al.
patent: 2004/0171064 (2004-09-01), Dahlen et al.
patent: WO 91/09627 (1991-07-01), None
patent: WO 02/083913 (2002-10-01), None
patent: WO 03/020123 (2003-03-01), None
Ishii, Junnichi et al., “Early Risk Stratification Using Cardiac Troponin T and Brain Natriuretic Peptide in Patients with Congestive Heart Failure.” Supplement toCirculation, vol. 110, No. 18, Nov. 2, 1999; p. I.679 XP009005614, 72ndScientific Sessions of the American Heart Asso., Nov. 7-10, 1999.
Croal, B.L. et al., “Cardiac Troponin I and Brain Natriuretic Peptide as Markers of Doxorubicin Cardiotoxicity,”Clinical Chemistry, vol. 47, No. S6, Jun. 2001 (2001-06); p. A149 XP001145792, 53rdAnnual Meeting of the AACC/CSCC, Chicago, Ill., Jul. 29-Aug. 2, 2001.
Langenbach, M.R., et al., “Das Atriale Natriuretische Peptid als Indikator einer Milden Postoperativen Kardialen Dysfunktion Nach Unkomplizierter Bypasschirurgie,”Zeitschrift Fuer Karkiologie, vol. 89, No. 12, 2000, pp. 1133-1140; XP 002231029.
Li, D. et al, “Greater Frequency of Increased Cardiac Troponin T than Increased Cardiac Troponin I in Patients with Chronic Renal Failure,”Chemical Chemistry, CLCHAU 42 (1) 114-115 (1996).
McCullough, P. et al., “Beyond Serum Creatinine: Defining the Patient with Renal Insufficiency and Why?”Reviews in Cardiovascular Medicine, vol. .4, Suppl 1 2003, S2-S6.
McCullough, P., et al., “B-type Natriuretic Peptide and Renal Function in the Diagnosis of Heart Failure: An Analysis From the Breathing Not Properly Multinational Study,”Am. J. of Kidney Diseases, vol. 41, No. 3 (Mar.) 2003; pp. 571-579.
Ziesche, S., et al. “Interobserver Discordance in the Classification of Mechanisms of Death in Studies of Heart Failure,”J. of Cardiac Failure, vol. 1, No. 2, Mar. 1995, pp. 127-132.
Nolan, J., et al., “Prospective Study of Heart Rate Variability and Mortality in Chronic Heart Failure,”Results of the UK Heart Failure Evaluation and Assessment of Risk Trial (UK-Heart), 1998 pp. 1510-1516.
Ishii, J., et al., “Prognostic Value of Combination of Cardiac Troponin T and B-Type Natriuretic Peptide after Initiation of Treatment in Patients with Chronic Heart Failure,”Clinical Chemistry, 49:12, 2020-2026 (2003).
Ishii, J., et al., “Risk Stratification Using a Combination of Cardiac Troponin T and Brain Natriuretic Peptide in Patients Hospitalized for Worsening Chronic Heart Failure,”Amer. J. of Cardiology, vol. 89, pp. 691-695, Mar. 15, 2002.
Ishii J., et al., “Plasma concentration of brain natriuretic peptide as a biochemical marker for the evaluation of right ventricular overload and mortality in chronic respiratory disease,”Clinica Chimica Acta, 301 (2000) 19-30.
De Lemos et al., “The Prognostic Value of B-Type Natriuretic Peptide in Patients with Acute Coronary Syndromes,”The New England Journal of Medicine, vol. 345, No. 14, Oct. 4, 2001.
Chen et al., “The natriuretic peptides in heart failure: Diagnostic and therapeutic potentials,”Proc. Assoc. Amer. Phys.vol. 111, No. 5, pp. 406-416, 1999.
Moe et al., “Neurohormonal activation in severe heart failure: Relations to patient death and the effect of treatment with flosequinan,”Amer. Heart J., vol. 139, No. 4, pp. 588-595, 2000.
Maisel et al., “Utility of B-natriuretic peptide as a rapid, point-of-care test for screening patients undergoing echocardiography to determine left ventricular dysfunction,”Amer. Heart J., Mar. 2001, pp. 368-374.
Hammerer-Lercher et al., “Head-to head comparison of N-terminal pro-brain natriuretic peptide, brain natriuretic peptide and N-terminal pro-atrial natriuretic peptide in diagnosing left ventricular dysfunction,”Clinica Chmica Acta310, pp. 193-197, 2001.
ACC Clinical Data Standards—Am. College of Cardiology Key Data Elements and Definitions for Measuring the Clinical Management and Outcomes of Patients with Acute Coronary Syndromes,J. Am. College of Cardiology, vol. 38, No. 7, Dec. 2001, pp. 2114-2130.
Mair et al., “Natriuretic peptides in assessment of left-ventricular dysfunction,”Scan. J. Lab. Invest.1999;59 (Suppl 230), pp. 132-142.
Wu, “Analytical and clinical evaluation of new diagnostic tests for myocardial damage,”Clinica Chimica Acta272:11-21, 1998.
Prickett et al., “Identification of Amino-Terminal Pro-C-Type Natriuretic Peptide in Human Plasma,”Biochem. Biophys. Res. Commun.286:513-517. 2001.
Ricchiuti, et al., “Cardiac troponin T isoforms expressed in renal diseased skeletal muscle will not cause false-positive results by the second generation cardiac troponin T assay by Boehringer Mannheim,”Clin. Chem.44:1919-1924, 1998.
Stein et al, “Natruiretic peptides: Physiology, therapeutic potential, and risk stratification in ischemic heart disease,”Amer. Heart J.135:914-923, 1998.
Ogawa et al., “Characterization of natriuretic peptide production by adult heart atria,”Am. J. Physiol.276:H1977-H1986, 1999.
Luchner et al., “Differential atrial and ventricular expression of myocardial BNP during evolution of heart failure,”Am. J. Physiol., 274:H1684-H1689, 1998.
Liew et al., “A catalogue of genes in the cardiovascular system as identified by expressed sequenced tags,”Proc. Natl. Acad. Sci. USA, 91:10645-10649, 1994.
Yu et al., “Plasma brain natriuretic peptide—an independent predictor of cardiovascular mortality in acute heart failure,”Eur. J. Heart Fail., 1:59-65, 1999.
Sagnella et al., “Atrail natriuretic peptide in human plasma—comparison of radioreceptor versus radioimmunoassay,”Clinica Chimica Acta.166:37-44 1987.
Jancin, “Rapid test helps identify cause of dyspnea—point-of-care brain natriuretic peptide immunoassay,”Family Practice News,May 1, 2000.
Apple et al., “Myocardial infarction redefined: Role of cardiac troponin testing,”Clin. Chem.47:377-379, 2001.
Ballerman, “A highly sensitive radioreceptor assay for atrial natriuretic peptide in rat plasma,”Amer. J. Physiol.254:F159-F163, 1988.
Bürgisser et al. “Human cardiac plasma concentrations of atrial natriuretic peptide quantified by radioreceptor assay;” 133:1201-1209, 1985.
Gutkowska et al., “Radioreceptor assay for atrial natriuretic factor,”Anal. Biochem.168:100-106, 1988.
Takemura et al., “Ventricular expression of atrial and brain natriuretic peptides in patients with nyocarditis,”Int. J. Cardiol.52:213-222, 1995.
Altemos et al., “Altered myocardial phenotype after mechanical support in human beings with advanced cardiomyopathy,”J. Heart Lung Transplant., 16:765-773, 1997.
Takemura et al., “Expression of atrial and
Jackowski George
Stanton Eric B.
Nanogen Inc.
Nguyen Bao-Thuy L.
Sughrue & Mion, PLLC
LandOfFree
Conjunctive analysis of biological marker expression for... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Conjunctive analysis of biological marker expression for..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Conjunctive analysis of biological marker expression for... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3742719